Astrocyte Pharmaceuticals Raises $9.5 Million Series B To Advance AST-004
By Amit Chowdhry ● Sep 30, 2026
Astrocyte Pharmaceuticals has raised $9.5 million in Series B funding to advance Phase 2 clinical development of AST-004, its investigational cerebroprotective therapy for concussion, traumatic brain injury and stroke. The financing was led by DeepWork Capital, with continued support from existing investors and participation from MintPharma Capital, Waterstar Capital, Dynagrow Capital and Angel Star Ventures.